EyePoint

EyePoint

Yahoo Finance • 5 days ago

Oracle and these 6 stocks are newest addition to Mizuho Top Picks list

Investing.com -- Mizuho Securities added software company Oracle Corp to its Top Picks list as a No. 1 pick, setting a $320 price target that is 25% above Bloomberg consensus on surging demand for its artificial-intelligence cloud services... Full story

Yahoo Finance • last month

Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls

Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled... Full story

Yahoo Finance • last month

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, GitLab, GLOBAL FOUNDRIES, Martin Marietta Materials, Rocket Lab USA, Strategy, Toast, Tower Semiconductor, and More

Quick Read All major indices closed lower Tuesday as war tensions and rising oil prices drove the Russell 2000 down 1% and Nasdaq down 1%. The 30-year Treasury bond hit 5.27%, its highest yield since 2007, while Brent Crude surged 5% to $... Full story

Yahoo Finance • 2 months ago

Ocular gains on EyePoint phase 3 wet AMD miss

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * Ocular Therapeutix (OCU... Full story

Yahoo Finance • 3 months ago

EyePoint to pay $4.6M to settle with DoJ over kickback claims

[Black stethoscope and US dollar bills on light blue background] Muhammad Labib Adilah/iStock via Getty Images The U.S. Department of Justice announced on Friday that EyePoint Pharmaceuticals (EYPT [https://seekingalpha.com/symbol/EYPT])... Full story

Yahoo Finance • 3 months ago

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announ... Full story

Yahoo Finance • 3 months ago

Citi's picks and pans for H2 '26: REITs, tech, consumer, health

[Citibank headquarters in Canary Wharf, London, UK] VV Shots Citi released its roadmap for the second half of 2026, including a macro-to-micro view of equity sectors. "Our recently revised S&P 500 (SPY [https://seekingalpha.com/symbol/SP... Full story

Yahoo Finance • 3 months ago

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could

Key Points Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billionglobal market Viking Therapeutics is on track to give... Full story

Yahoo Finance • 5 months ago

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

Key Points Cormorant Asset Management bought 5,800,000 Erasca shares in the first quarter, an estimated $68.55 million trade based on quarterly average pricing. The quarter-end position value rose by $93.84 million, reflecting both share... Full story

Yahoo Finance • 7 months ago

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside... Full story

Yahoo Finance • 7 months ago

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

On February 17, 2026, Parkman Healthcare Partners disclosed a new position in EyePoint(NASDAQ:EYPT), acquiring 1,088,033 shares in the fourth quarter. What happened According to a Securities and Exchange Commission (SEC) filing dated Feb... Full story

Yahoo Finance • 7 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]) * Abercrombie & Fitch Co. (ANF [https://seekingalpha.com/symbol/ANF]) * XAI Octagon Floating Rate & Alternative Inc... Full story

Yahoo Finance • 7 months ago

Pre-Market Earnings Report for March 4, 2026 : DY, NXE, BBWI, ANF, WIX, EYE, EYPT, GENI, DAKT, STVN, OCGN, REAX

The following companies are expected to report earnings prior to market open on 03/04/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Dycom Industries, Inc. (DY)is reporting for the quarter ending Janua... Full story

Yahoo Finance • 10 months ago

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F as... Full story

Yahoo Finance • 11 months ago

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LU... Full story

Yahoo Finance • 11 months ago

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program consisting of two identical non-inferiority tria... Full story

Yahoo Finance • 11 months ago

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story

Yahoo Finance • 12 months ago

Biggest stock movers Wednesday: VERI, PZZA, and more

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures edged up early Wednesday, as investors braced for a busy day of corporate earnings reports and watched for signals on the Federal Reserv... Full story

Yahoo Finance • 12 months ago

EyePoint prices public offering at $12.00 per share, raises $150M to boost DURAVYU™ Phase 3 clinical programs

EyePoint Pharmaceuticals (NASDAQ:EYPT [https://seekingalpha.com/symbol/EYPT]) has announced the pricing [https://seekingalpha.com/pr/20266005-eyepoint-announces-pricing-of-public-offering] of an underwritten public offering expected to gen... Full story

Yahoo Finance • 12 months ago

EyePoint Announces Pricing of Public Offering

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas... Full story